October 26, 2021
Eli Lilly Japan’s migraine treatment lasmiditan succinate, known as Reyvow in the US, will come up for discussion by a key health ministry advisory committee on November 5. The drug follows the company’s Emgality (galcanezumab) launched earlier this year within...read more